II. AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

Claims 1-7 (Withdrawn)

Claim 8 (Currently Amended) A compound ~~according to claim 1~~, of the Formula I



I

wherein

Z_1 is selected from the group consisting of CH_2, O, CH_2O, NH, CO, S, SO, CH(OH) and SO_2;

Z_2 is a 1-5 carbon linker optionally containing one or more heteroatom selected from the group consisting of O, S and N; or

Z_1 - Z_2 optionally contain a carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, or acyl group; wherein the carbon and nitrogen atoms of Z_1 - Z_2 are optionally substituted by a substituent selected from the group consisting of alkyl, alkoxy, thioalkyl, alkylsulfone, aryl, alkoxyalkyl, alkylamino, heteroaryl, hydroxy, alkenyl, alkynyl, carboxyalkyl, halogen, haloalky and acylamino;

n is an integer 0, 1 or 2;

R^c is selected from the group consisting of hydrogen; alkyl; halogen, hydroxy, nitro, alkoxy, amino, haloalkyl, aryl, heteroaryl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, thioalkyl, alkylamino, arylamino, alkylsulfonylamino, acyl, acylamino, sulfonyl, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, alkynylalkyl, carboxy, alkoxycarbonyl, carboxamido, cyano, and -

$(CH_2)_n$-COR wherein n is 0-2 and R is selected from the group consisting of hydroxy, alkoxy, alkyl and amino;

X is selected from the group consisting of -O-, CO, SO_2, NR^m and $(CHR^p)_n$; wherein R^p and R^m are H or alkyl, n is 0-2;

a'

R^b is X_3 - R^h wherein X_3 is selected from the group consisting of O, S and NR^j wherein R^h and R^j are independently selected from the group consisting of H, alkyl, acyl, aryl, aralkyl and alkoxyalkyl; and

the ring A-B 

is 

; and

A^1 is selected from the group consisting of:











B^1 = CH_2, O, CO, S, CF_2, SO_2, NR
R^{79} = OR, OH, H, Me m = 1 or 2















B^2 = N, CH

B^3 = N, CH

B^4 = NH, O, S











B^5 = NH, O, S

B^6 = N, CH
R^{80} = H, Me

X = O, S, NR, SO_2, CF_2

X = CH_2, O, S, NR, SO_2, CONR

B^7 = CH_2, O, CO, S, CF_2, SO_2, NR
R^{81} = OR, OH, Me

and pharmaceutically acceptable salts, isomers, enantiomers, tautomers, racemates ~~and~~ or polymorphs thereof.

a1

Claim 9 (Currently Amended) A compound according to claim ~~1~~ 8 ~~selected from the group consisting of:~~ wherein said compound is

~~[2,2-dimethyl-3-oxo-8-[3-(pyridin-2-ylamino)propoxy]-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]acetic acid;~~

~~1,2,3,4-tetrahydro-6-[3-(2-pyridinylamino)propoxy-2-isoquinoline-propanoic acid;~~

~~{5-[3-(pyridin-2-ylamino)propoxy]-1H-indol-1-yl}acetic acid;~~

~~2,3-dihydro-5-[3-(2-pyridinylamino)propoxy]-1H-indene-2-acetic acid;~~

~~2, 3, 4, 5-tetrahydro-5-oxo-8-[3-(2-pyridinylamino)propoxy]-1,4-benz-oxazepine-4-acetic acid;~~

~~2,3,4,5-tetrahydro-8-[3-(2-pyridinylamino)propoxy]1,4-benzoazepine-4-acetic acid;~~

1,2,3,4-tetrahydro-1-oxo-6-[3-(2-tetrahydropyrimidinyl)amino]-propoxy]-2-isoquinolineacetic acid;

~~3,4-dihydro-7-[3-(2-pyridinylamino)propoxy]-2-H-1-benzopyran-3-acetic acid;~~

~~(6-{[3-(pyridin-2-ylamino)propyl]thio}-1,2,3,4-tetrahydronaphthalen-2-yl)acetic acid;~~

~~1,2,3,4-tetrahydro-6-[2-(5,6,7,8-tetrahydro-1,8-naphthyridyl)-amino-ethyloxy]2-naphthaleneacetic acid~~, and pharmaceutically acceptable salts, isomers, enantiomers, tautomers, racemates ~~and~~ or polymorphs thereof.

Claim 10 (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of ~~Claims 1-9~~ Claim 8 and a pharmaceutically acceptable carrier.

Claim 11 (Currently Amended) A method for treating conditions mediated by the $\alpha_v\beta_3$ integrin in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound of ~~Claims 1-9~~ Claim 8.

a'

Claim 12 (Currently Amended) The method according to Claim 11 wherein the $\alpha_v\beta_3$ integrin-mediated condition treated is selected from the group consisting of tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy, and arthritis.

Claim 13 (Currently Amended) A method for treating conditions mediated by the $\alpha_v\beta_5$ integrin in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_5$ inhibiting amount of a compound of ~~Claims 1-9~~ Claim 8.

Claim 14 (Currently Amended) The method according to Claim 13 wherein the $\alpha_v\beta_5$ integrin-mediated condition treated is selected from the group consisting of tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy, and arthritis.

Claim 15 (Currently Amended) A method of treating neoplasia in a patient in need thereof comprising administering a compound of ~~Claims 1-9~~ Claim 8 in combination with a chemotherapeutic agent.

Claim 16 (Currently Amended) A compound of ~~Claims 1-9~~ Claim 8 that selectively antagonizes the $\alpha_v\beta_3$ and the $\alpha_v\beta_5$ integrins, over the $\alpha_v\beta_6$ integrin.